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Correlation between hyperglycemia 
and glycated albumin 
with retinopathy of prematurity
Ana C. Almeida1,2,3,4,5*, Gabriela A. Silva6, Gabriele Santini7, Margarida Brízido1, 
Miguel Correia8, Constança Coelho9 & Luís Miguel Borrego3,4,10
To determine the association between hyperglycemia, glycated albumin (GlyA) and retinopathy of 
prematurity (ROP). Prospective study of all infants under ROP screening from March 2017 to July 
2019. All demographic, clinical and laboratory data were collected. Glucose was measured at birth 
and every 8 h for the first week and serum GlyA was evaluated at birth, 1st, 2nd and 4th weeks after 
birth. Reference range for GlyA was obtained. Univariate logistic regression was used to examine risk 
factors for ROP followed by multivariate regression. A total of 152 infants were included in the study. 
Median gestational age was 30 weeks and median birth weight 1240 g. Thirty-three infants (21.7%) 
had ROP. Hyperglycemia was present in 24 (72.7%) infants diagnosed with any ROP versus 6 (0.05%) 
in those without ROP. Median GlyA at birth, 1st, 2nd and 4th and respective reference ranges were 
8.50% (6.00–12.65), 8.20% (5.32–11.67), 8.00% (5.32–10.00) and 7.90% (5.30–9.00) respectively. After 
multivariate logistic regression, hyperglycemia but not GlyA, remained a significant risk factor for 
ROP overpowering the other recognized risk factors (Exp (B) 28.062, 95% CI for Exp(B) 7.881–99.924 
p < 0.001). In our cohort, hyperglycemia but not GlyA, remained a significant risk factor for ROP 
overpowering the other recognized risk factors.
Retinopathy of prematurity (ROP) is a neovascular disorder of the immature retina and a leading cause of pre-
ventable blindness  worldwide1,2. Neonatal hyperglycemia is a common problem in extremely preterm infants 
that has been linked to increased mortality and  morbidity3,4. Several studies have also reported an association 
between hyperglycemia and  ROP5–17.
Glycation of various proteins is known to occur at higher rate in individuals with  hyperglycemia18,19. Albumin 
is more sensitive to glycation than other proteins, mainly because of its high concentration and long half-life and 
also due to the large number of lysine and arginine residues that may be involved in the formation of early and 
advanced glycation  products19. Similarly to HbA1c, glycated albumin (GlyA) can be used as a clinical marker 
for ROP. GlyA is especially useful in newborns, as high levels of fetal hemoglobin affect HbA1c measurements 
and reflects plasma glucose levels over a shorter period due to the shorter half-life of serum albumin when 
compared to  erythrocytes20,21.
The objective of this study was to determine the association between hyperglycemia, GlyA and ROP.
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Methods
Study population. This was a prospective cohort study of all preterm infants who underwent ROP screen-
ing from March 2017 to July 2019, in two neonatal intensive care units from two institutions in Portugal. The 
study was approved by the Ethical Review Boards of Hospital São Francisco Xavier—Centro Hospitalar de Lis-
boa Ocidental and Hospital Beatriz Ângelo, as well as by the National Data Protection Authority (CNPD—
Comissão Nacional de Proteção de Dados) and the Ethics Committee of the Nova Medical School. It was carried 
out in compliance with the principles of the Declaration of Helsinki, in its latest version (Brazil, 2003).
Following the current Portuguese screening guidelines, all infants with gestational age (GA) ≤ 32 weeks, 
birth weight (BW) ≤ 1.500 g, or being at higher risk of ROP determined by a neonatologist are eligible for ROP 
screening and were included in the  study22. Infants without a known ROP outcome, and those with any ocular 
diseases apart from ROP were excluded.
Data collection. For ROP screening, an initial fundus examination was performed at 32 weeks of postmen-
strual age (PMA) or at 4 weeks of chronological age, whichever was later. The diagnosis of ROP and indication 
of treatment for ROP followed the International Classification of ROP  Revisited23 and the Early Treatment for 
ROP  Study24, respectively. The term severe ROP included both “type 1 ROP” and “type 2 ROP” both defined by 
the criteria of the Early Treatment for ROP  study24.
Demographic and ophthalmologic data, medications, laboratory results, diagnosis, procedures and maternal 
history were collected.
Following the neonatal units’ protocol, glucose concentration was measured at birth and daily, every 8 h, 
during the first week using a point-of-care glucometer. For any glucose reading of ≤ 50 or ≥ 150 mg/dl, a serum 
sample was sent to the laboratory for confirmation. Infants were stratified into two groups: a hyperglycemia group 
(when plasma glucose concentrations exceeded > 150 mg/dl at least once for the first 7 days after birth) and an 
euglycaemia group (50–150 mg/dl). Hypoglycemia was defined as blood glucose ≤ 50 mg/dl.
Serum GlyA was evaluated at birth, 1 week, 2 and 4 weeks after birth using the leftover blood collected for 
purposes other than the study. Serum GlyA was determined by an enzymatic method using albumin-specific 
protease, ketoamine oxidase and albumin assay reagent (QuantILab Glycated Albumin, Instrumentation Labora-
tory SpA—A Werfen Company, Milan, Italy). GlyA was hydrolyzed by an albumin-specific protease, and then 
oxidized by ketoamine oxidase to produce hydrogen peroxide, which was measured quantitatively. Serum GlyA 
levels were calculated as the percentage of GlyA relative to total albumin, which was measured in the same serum 
sample using the bromocresol purple  method25,26.
Statistical methods. Univariate logistic regression was used to examine risk factors for ROP. In this analy-
sis, we evaluated GA, BW, sex, small for GA status, gestational diabetes, hyperglycemia, exposure to insulin, 
GlyA (birth, 1st, 2nd and 4th week after birth), days before first discharge, hyaline membrane disease, bron-
chopulmonary dysplasia, need of oxygen > 28 days, days of mechanical ventilation, days of oxygen supplemen-
tation, thrombocytopenia (≤ 50,000 platelets per microliter), thrombocytosis (≥ 500 ×  103/l), postnatal steroids 
(dexamethasone), early red cell transfusion (first 10 days after birth), total red cell transfusions, anemia (< 11 g/
dl) during the first week after birth, persistent ductus arteriosus, peri and intraventricular hemorrhage, diuretics 
(furosemide), days of phototherapy, early and late onset sepsis, necrotizing enterocolitis (NEC) and absence of 
maternal milk.
Univariate analysis was followed by multivariate regression (backward conditional) using variables that were 
significant on univariate and clinically important. Each multivariable logistic regression analysis included a maxi-
mum of four independent variables always with the same dependent value, which was presence, or absence of 
ROP. All multivariable regression analyses were performed using a backward conditional method. We considered 
a p < 0.05 statistically significant. Reference range for GlyA was obtained according to the CLSI EP28-A3C27. 
Data analysis was performed using the SPSSv23 (IBM, USA).
Ethics approval and consent to participate. This research complies with the guidelines for human 
studies and was conducted ethically in accordance with the World Medical Association Declaration of Helsinki. 
Parents/guardians have given their written informed consent and the study protocol was approved by the rel-
evant ethics committees (Ethical Review Board of Centro Hospitalar de Lisboa Ocidental reference number 172/
CES—2015; Ethical Review Board of Hospital Beatriz Ângelo reference number 1944/2017_MJHNO; National 
Data Protection Authority (CNPD—Comissão Nacional de Protecção de Dados) reference number 9377/2016 
and the Ethics Research Committee NMS|FCM-UNL (CEFCM) reference number 28/2016/CEFCM).
Results
A total of 152 infants were included in the study. Median GA was 30 weeks (range 24–36 weeks) and the median 
BW was 1240 g (range 408–2670 g). Thirty-three infants (21.7%) developed ROP, 20 (13.2%) severe ROP and 6 
(3.9%) Type 1 ROP (Tables 1, 2).
Hyperglycemia was present in 24 (72.7%) infants diagnosed with ROP versus 6 (5.0%) without ROP. Median 
glycaemia was 95 mg/dl in infants with ROP and 85 mg/dl in those without (p < 0.001). The median number of 
occurrences of hyperglycemia in the first week was 2 (range 1–6). No infant required insulin. Postnatal steroids 
were all prescribed after the first month after birth.
An interim analysis of GlyA was made for the first 94 infants included in the study (Table 3). Having more 
than half of the cohort analyzed and since GlyA was not found to be a significant risk factor (p = 0.629, p = 0.408, 
p = 0.278, p = 0.064, at birth, 1 week, 2 week and 4 week, respectively), it was decided not to pursue with its 
analysis to all cohort.
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GlyA values in infants that were not treated with postnatal corticosteroids permitted us to determine a 
reference range according to the CLSI EP28-A3C27 (Table 4). There was no statistical difference in GlyA values 
between infants that received prenatal corticoids vs. those who did not (p = 0.557, 0.153, p = 0.361, p = 0.831 at 
birth, 1 week, 2 week and 4 week, respectively).
Risk factors for ROP identified in univariate logistic regression were GA, BW, hyperglycemia, days before 
first discharge, hyaline membrane disease type 3, bronchopulmonary dysplasia, need of oxygen > 28 days, days 










24–25 2 (1.6) 5 (15.2) 5 (25.0) 4 (66.7)
26–27 8 (6.7) 10 (30.3) 6 (30.0) 1 (16.7)
28–29 23 (19.3) 12 (36.4) 6 (30.0) 1 (16.7)
30–32 70 (58.8) 6 (18.2) 3 (15.0) 0 (0.0)
 > 32 16 (13.4) 0 (0.0) 0 (0.0) 0 (0.0)
Birth weight (g)
 < 750 5 (4.2) 13 (39.4) 9 (45.0) 3 (50.0)
750–1000 13 (10.9) 9 (27.3) 5 (25.0) 2 (33.3)
1001–1500 78 (65.5) 11 (33.3) 6 (30.0) 1 (16.7)
1501–1800 20 (16.8) 0 (0.0) 0 (0.0) 0 (0.0)
 > 1801 3 (2.5) 0 (0.0) 0 (0.0) 0 (0.0)
Total 119 33 20 6
Table 2.  Characteristics of the included infants. NEC necrotizing enterocolitis. *Grade 1–4. ** ≤ 50 000 
platelets per microlite. + First 10 days after birth. ++ Hemoglobin < 11 g/dl. +++ Grade I–IV.
n
Total cohort No ROP Any ROP Severe ROP Type 1 ROP
152 119 33 20 6
Male, n (%) 78 (51.3) 65 (54.6) 13 (39.4) 9 (45.0) 2 (33.3)
Gestational age (weeks) (median, range) 30 (24–36) 31 (24–36) 28(24–32) 27 (24–30) 25 (24–29)
Birth weight (g) (median, range) 1240 (408–2670) 1335 (500–2670) 825 (408–1340) 770 (408–1340) 736 (589–110)
SGA, n (%) 37 (24.3) 27 (22.7) 10 (30.3) 7 (35.0) 2 (33.3)
Gestational diabetes, n (%) 18 (11.8) 14 (11.7) 4 (12.1) 2 (10) 0 (0.0)
Hyperglycemia, n (%) 30 (19.7) 6 (5.0) 24 (72.7) 15 (75.0) 4 (66.7)
Hyaline membrane disease* n (%) 132 (86.8) 101 (84.8) 31 (93.9) 18 (90.0) 6 (100.0)
Bronchopulmonary dysplasia, n (%) 43 (28.3) 20 (16.8) 23 (69.6) 15 (75.0) 6 (100.0)
Need of oxygen > 28 days, n (%) 47 (30.9) 22 (18.5) 25 (75.8) 17 (85.0) 6 (100.0)
Days of mechanical ventilation (median, 
range) 0 (0–86) 0 (0–86) 7 (0–82) 17 (0–60) 24 (0–60)
Days of oxygen supplementation (median, 
range) 10 (0–226) 8 (0–226) 46 (1–221) 72 (1–221) 89 (41–221)
Thrombocytopenia** n (%) 47 (30.9) 33 (27.7) 14 (42.4) 10 (50.0) 3 (50.0)
Prenatal steroids for pulmonary maturation 
n (%) 139 (91.4) 108 (90.8) 31 (93.9) 19 (95.0) 5 (83.3)
Postnatal steroids n (%) 7 (4.6) 3 (2.5) 4 (12.1) 3 (15) 3 (50.0)
Early red cell  transfusion+ n (%) 27 (17.8) 10 (8.4) 17 (51.5) 13 (65.0) 5 (83.3)
Total red cell transfusions (median, range) 0 (0–13) 0 (0–8) 2 (0–13) 4 (0–13) 7 (0–9)
Anemia first week of  life++ n (%) 25 (16.4) 11 (9.2) 14 (42.4) 10 (50.0) 3 (50.0)
Persistent ductus arteriosus n (%) 22 (16.4) 14 (11.7) 8 (24.2) 5 (25.0) 2 (33.3)
Peri and intraventricular  hemorrhage+++ 
n (%) 46 (30.3) 29 (24.4) 17 (51.5) 14 (70.0) 5 (83.3)
Furosemide n (%) 38 (25.0) 20 (16.8) 18 (54.5) 13 (65.0) 4 (66.7)
Days of phototherapy (median, range) 3 (0–15) 3 (0–15) 4 (0–9) 4 (0–9) 4 (2–7)
Early onset sepsis n (%) 55 (36.2) 38 (31.9) 17 (51.5) 13 (65.0) 4 (66.7)
Late onset sepsis n (%) 60 (39.5) 37 (31.1) 23 (69.6) 15 (75.0) 3 (50.0)
NEC n (%) 8 (5.3) 2 (1.7) 6 (18.2) 5 (25.0) 1 (16.7)
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of mechanical ventilation, days of oxygen supplementation, early red cell transfusion (first 10 days after birth), 
total red cell transfusions, anemia (< 11 g/dl) during the first week after birth, late onset sepsis, diuretics and NEC.
Risk factors identified after multivariate logistic regression included BW, hyperglycemia, need of oxy-
gen > 28 days and NEC (Table 5).
Discussion
Despite recent advances in neonatal care, ROP remains a great source of morbidity among the very low weight 
 infants1. While immaturity and supplemental oxygen are already known major risk factors, ROP is a multifac-
torial disease process with many associated risk  factors17. Our aim was to determine the association between 
hyperglycemia, GlyA and ROP and further compare them with other known risk factors. After multivariate 
logistic regression, hyperglycemia but not GlyA, remained a significant risk factor for ROP overpowering the 
other recognized risk factors.
Hyperglycemia is a common metabolic disturbance affecting up to 80% of very low birth  infants4,28. In preterm 
infants, it has been associated with low insulin like growth factor 1 (IGF-1) levels, which are essential for adequate 
retinal  neovascularization29. Hyperglycemia is associated to oxidative stress and leads to increased resistance of 
vessel walls and changes in organ blood flow, thus exacerbating retinal  hypoxia30.
Garg et al., in a retrospective case–control study of 16 infants were the first to associate increased glucose levels 
in the initial month after birth to  ROP17. Since then, 10 retrospective  studies5–7,10–16 and one prospective  study8 
reported a significant association between hyperglycemia and ROP. Lee et al.31 in a retrospective study of 24,548 
infants with hyperglycemia, (blood glucose > 180 mg/dl), concluded that hyperglycemia alone was not associated 
with severe ROP. However, blood glucose > 150 mg/dl and insulin use were associated with severe ROP. In our 
study, hyperglycemia was defined as blood glucose > 150 mg/dl but no infant needed insulin.
In 2019, a study by Jagla et al.32 reported that higher glycemic variability during the first week after birth 
was associated with treatment requiring ROP. However, this association was lost on logistic regression. This loss 
might be due to real-time clinical intervention correcting the glucose level and limiting its consequences or due 
to the inability to detect differences due to relatively small sample size (n = 152). The same author assessed the 
association between glycemic variability in the 1st week after birth and type 1 ROP in a case–control study of 40 
premature infants. After multiple regression, risk of type 1 ROP was only found to be associated with duration 
of oxygen exposure and higher glycemic  variability33. More recently, Cakir et al.29 in a cohort of 117 infants, 
reported that mean plasma glucose levels > 135.32 mg/dl during first week after birth were associated with lower 
postnatal IGF-1 levels and increased risk of ROP. These findings were replicated in a neonatal hyperglycemia 
oxygen-induced retinopathy mouse model, demonstrating that decreased insulin signaling suppressed liver 
production, lowered serum IGF-1 levels and increased retinal neovascularization. In our cohort, the median 
glycaemia was 95 mg/dl in infants with ROP and 85 mg/dl in those without, supporting that the difference in 
median glycaemia between these two groups is not large. Nevertheless, a trend for higher glycaemia does seem 
to exist in infants that develop ROP. Furthermore, and in line with the studies mentioned above, we also found 
Table 3.  Summary of glycated albumin values (serum glycated albumin (GA) levels are calculated as the 
percentage of GA relative to total albumin).
Glycated albumin (%) All (n = 94) No ROP (n = 74) Any ROP (n = 20)
Birth Median (%) (range) 8.50 (6.30–17.50) 8.50 (6.30–17.50) 8.50 (7.20–10.10)
1 week after birth Median (%) (range) 8.20 (5.30–12.10) 8.20 (5.30–12.10) 8.10 (6.50–10.50)
2 weeks after birth Median (%) (range) 8.00 (5.10–18.20) 7.90 (5.50–18.20) 8.30 (5.10–10.00)
4 weeks after birth Median (%) (range) 7.90 (5.50–10.00) 7.90 (5.50–10.00) 7.75 (6.50–9.80)
Table 4.  Reference range for glycated albumin in preterm infants (serum glycated albumin (GA) levels are 
calculated as the percentage of GA relative to total albumin).
At birth First week Second week Fourth week
Glycated albumin reference range (%) 6.000–12.650 5.325–11.675 5.325–10.000 5.300–9-000
Table 5.  Risk factors for ROP after multivariate regression analyses.
B Exp(B) 95% CI for Exp(B) p-value
Birth weight  − 0.004 0.996 0.993–0.998  < 0.001
Hyperglycemia 3.334 28.062 7.881–99.924  < 0.001
Oxygen > 28 days 2.399 11.012 3.132–38.716  < 0.001
Necrotizing enterocolitis 2.617 13.693 1.361–131.714 0.026
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that the presence of any event related to hyperglycemia was more frequent in infants diagnosed with ROP versus 
in those without (72.7% vs. 5.0%) even after multivariate analysis.
Due to the proposed association between hyperglycemia and ROP, the authors tried to uncover if GlyA’s values 
differed between infants with and without ROP and if so, if it would serve as clinical marker for ROP. Analogously 
to HbA1c, GlyA is one of the clinical markers for glycemic control and has been proven to be useful in the care 
of patients with neonatal diabetes  mellitus18,34,35. Its main advantage over the widely used HbA1c, is that GlyA 
is not affected by hemoglobin’s metabolism or its  variants35. Neonatal blood contains a high proportion of fetal 
hemoglobin (HbF)20,36. Additionally, preterm infants commonly undergo red blood cell transfusions which would 
also impair true evaluation of glycemic control with HbA1c. GlyA has a high specificity as it reflects glycation 
products of a single protein, is not affected by the concentration of serum protein because it is expressed as a 
ratio to albumin, nor is affected by other  proteins34.
In the particular case of infants at risk for ROP, GlyA has the advantage of reflecting plasma glucose levels 
over a shorter period. Because the half-life of serum albumin (14 days) is shorter than that of erythrocytes, it 
reflects the status of glycemic control changes for 2–4  weeks20,35. Moreover, GlyA reflects the fluctuation of plasma 
glucose as well as the mean plasma  glucose34, thus having the potential of reflecting the glycemic control during 
the first phase of ROP. Due to the exploratory nature of our study the authors believed that the chosen sampling 
intervals (birth, 1 week, 2 and 4 weeks) would maximize the ability to detect relevant changes. Koga et al.36 have 
previously studied the GlyA levels in the umbilical cord blood of 5 neonates at birth. Serum median GlyA level 
was 9.4 ± 1.1% (slightly lower than the lower limit of normal controls for adults). Suzuki et al.20 tried to establish 
the reference intervals for GlyA in 58 healthy full-term newborn infants. Age-dependent reference values (95% 
CI) for GlyA in infants were between 4.9–9.4% at 4–7 days, 5.5–10.1% 7–14 at 7–14 days and 6.2–10.8% at 
2–4 weeks. In our cohort, the obtained median GlyA values in the 4 time points were similar to those reported 
by Suzuki et al. albeit with a greater range of values.
Because this was a proof of concept an interim analysis of GlyA was made halfway thru the study and it was 
found that GlyA alone was not a significant risk factor and therefore it was decided not to continue this analy-
sis. GlyA can be altered in patients with albumin metabolism  disorders20. None of our infants had nephrotic 
syndrome, or altered thyroid function, however most of them received prenatal corticoids. Two studies have 
reported the effect of antenatally administered corticosteroids: one study did not show an effect on whole body 
amino acid  metabolism37, whereas in another, infants that received prenatal corticosteroids for lung maturation 
tended to have a 37% increase in albumin synthesis, although not statistically  significant38. In our study there was 
no statistical difference in GlyA values between infants that received prenatal corticoids vs. those who did not.
Yudkoff et al. reported that the relatively low serum albumin concentrations, typical of premature infants, 
appear to be referable to more rapid turnover of a small plasma pool rather than a diminution in the rate of 
albumin  synthesis39. It is possible that the rapid turnover did not allow for sufficient glycation. Other possible 
reason for the lack of difference between GlyA in ROP and non-ROP infants might be due to the insufficient 
duration of hyperglycemia. Both data from the Continuous Glucose Monitoring in Very Preterm  Infants40 and 
from 2 other similar  studies28,32 monitoring the first week after birth reported that the time spent in the predefined 
hyperglycemia was low (2.3% to 10.3%28,32,40). One hypothesis is that the occurrence rather than the duration of 
hyperglycemia might be associated with ROP.
Although not significant as a risk factor, with this study, we provide a reference range for GlyA at four dif-
ferent time points in premature infants that can be useful to assess the accurate glycemic status in these babies. 
Neonatal diabetes may affect gestational age and so a percentage of patients could present prematurely, or certain 
mutations may result in premature  birth41. In a cohort of 750 patients with neonatal diabetes, 16% of patients 
with a genetic diagnosis were born  prematurely41. There are several limitations of our study, namely the small 
cohort, the use of ROP rather than treatment requiring ROP (due to limited sample size) and the inclusion of 
only two institutions from the same geographical area. We also recorded hyperglycemic events rather than its 
duration, due to the inability to continuously monitor the glucose level in the entire cohort.
In conclusion, after multivariate analysis, the classic known risk factors—BW, need of oxygen > 28 days and 
NEC—continued to be associated with ROP. Nevertheless, hyperglycemia remained a significant risk factor for 
ROP, overpowering the other recognized risk factors. Although not linked to an increased risk of ROP we have 
provided for the first time a reference range for GlyA in premature infants, that can be used in future studies 
as a tool to evaluate glycemic control. Future studies should aim to prospectively investigate the effects of glu-
cose control, preferably with continuous monitoring, in larger cohorts of premature infants, to better ascertain 
whether blood glucose level/variability is a specific risk factor for ROP or rather an indirect marker reflecting 
the severity of the newborns’ morbidity, and in turn conferring a higher risk for ROP.
Data availability
The datasets used and/or analyzed during the current study are available from the corresponding author upon 
reasonable request.
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